Journey Medical Co. (NASDAQ:DERM) CFO Sells $51,002.28 in Stock

Journey Medical Co. (NASDAQ:DERM) CFO Joseph Benesch sold 9,324 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $5.47, for a total transaction of $51,002.28. Following the sale, the chief financial officer now owns 47,331 shares of the company’s stock, valued at approximately $258,900.57. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Joseph Benesch also recently made the following trade(s):

• On Tuesday, July 23rd, Joseph Benesch sold 4,055 shares of Journey Medical stock. The stock was sold at an average price of $5.40, for a total transaction of $21,897.00.

Journey Medical Stock Performance

Shares of Journey Medical stock opened at $5.23 on Friday. The stock’s fifty day simple moving average is $5.18. Journey Medical Co. has a 1 year low of $1.78 and a 1 year high of $8.11. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94. The stock has a market cap of $104.65 million, a P/E ratio of -16.87 and a beta of 0.93.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.27). Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. The company had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.91 million. As a group, equities analysts expect that Journey Medical Co. will post -0.95 earnings per share for the current year.

Institutional Investors Weigh In On Journey Medical

Several hedge funds have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. purchased a new position in Journey Medical during the 2nd quarter worth $1,664,000. Acadian Asset Management LLC increased its stake in shares of Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after acquiring an additional 194,389 shares during the period. Rosalind Advisors Inc. purchased a new position in Journey Medical during the second quarter worth about $644,000. Heron Bay Capital Management acquired a new stake in Journey Medical in the first quarter valued at about $124,000. Finally, Nwam LLC purchased a new stake in Journey Medical in the 1st quarter valued at approximately $41,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DERM has been the topic of several research reports. Roth Capital raised Journey Medical to a “strong-buy” rating in a report on Friday, June 28th. Roth Mkm initiated coverage on Journey Medical in a research note on Friday, June 28th. They set a “buy” rating and a $11.00 price target on the stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.